• P3 Health Partners on April 27, 2026 agreed to issue up to USD 70 million of units in a private placement to affiliates of Chicago Pacific Founders.
• Initial closing sold USD 10 million of units, with up to USD 60 million available in future tranches.
• Units include Series D 19.5% Cumulative Preferred Stock, which is unregistered and not listed.
• Units also include 7-year warrants to buy Class A common stock equal to 0.66333% of outstanding Class A and Class V shares per USD 1 million funded.
• Registration rights agreement requires filing a resale registration statement for shares issuable on warrant exercise, subject to any Nasdaq stockholder approval requirement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. P3 Health Partners Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001832511-26-000018), on April 28, 2026, and is solely responsible for the information contained therein.